Drug executives hedge on lowering prices

Executives from 7 drug companies appear before the Senate. Photo: Win McNamee/Getty Images

Drug companies have cheered the Trump administration's proposed crackdown on industry middlemen, but some hedged this morning when asked whether that plan would cause them to lower their prices.

The big picture: Pharmaceutical executives have stayed firmly on message even amid some tough questioning from the Senate Finance Committee.

What they're saying: Several lawmakers have taken a tough tone against the 7 executives testifying this morning about drug prices.

  • Sen. Ron Wyden (D-Ore.), for example, said AbbVie "protects the exclusivity of Humira like Gollum with his ring."
  • The pharmaceutical executives in attendance responded with many of the industry's standard arguments, including broadsides against pharmacy benefit managers and the drug rebate system PBMs rely on.

Between the lines: The Trump administration has proposed eliminating those PBM rebates in Medicare and Medicaid, saying that will also translate into lower sticker prices. Finance Chairman Chuck Grassley (R-Iowa) asked the executives whether they would, in fact, lower prices as a result of the rebate proposal.

  • AstraZeneca CEO Pascal Soriot and Merck CEO Ken Frazier both said their companies would lower drug prices if the rebate rule was applied to both the Medicare and commercial insurance markets. For now, it doesn't apply to commercial insurance.
  • Others said they similarly supported the rule, but hedged by saying costs would be lower for patients when they pick up the drug at the pharmacy — not necessarily that the health care system as a whole would be paying less.

What's next

Pelosi slams McConnell trial rules as "deliberately designed to hide the truth"

Photo: Mark Wilson/Getty Images

House Speaker Nancy Pelosi (D-Calif.) claimed in a statement Tuesday that the rules Senate Majority Leader Mitch McConnell (R-Ky.) has proposed for President Trump's impeachment trial diverge from the Clinton precedent and show he has "chosen a cover-up" over a fair trial.

Context: McConnell made public an organizing resolution Monday laying out the terms for the trial, which include 24 hours over two days for each side to present their cases. It would block evidence discovered in the House impeachment investigation from being presented without a separate vote, and would delay a vote on whether to subpoena witnesses and documents until later in the trial.

Setting the scene for Super Bowl LIV

Illustration: Sarah Grillo/Axios

After a grueling four months of football, Patrick Mahomes has led the Chiefs out of the darkness and into the Miami sun, where the 49ers football machine awaits them in the Super Bowl.

"The Gunslinger"

Mahomes is 24 years old, arguably the best player in football and he just toppled Tom Brady as the top seller of NFL merchandise. A star has already been born — now he has the biggest stage in sports to showcase his brilliance.

Go deeperArrow2 hours ago - Sports

Exclusive: The Athletic raises $50 million

Adam Hansmann (left) and Alex Mather (right), co-founders of The Athletic. Photo: Steph Gray, courtesy of The Athletic

The Athletic, a subscription-based digital sports media company, has raised $50 million in a Series D funding round, executives tell Axios.

  • With this investment, the company has raised a total of $139.5 million since its launch in 2016 and is valued at roughly $500 million after the new raise, according to sources familiar with the deal.
Go deeperArrow2 hours ago - Media